Herbal formula may help HIV patients whose immune systems Don't fully recover

NCT ID NCT07698574

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether adding Qiling Yiqi tablets, a Chinese herbal medicine, to standard HIV therapy can improve immune function in people whose CD4 counts remain low despite successful viral suppression. The trial involves 240 adults with HIV who have been on antiretroviral therapy for years but still have weak immune systems. Participants will take the herbal tablets or a placebo for 48 weeks, and researchers will measure changes in CD4 cell counts and other immune markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Qiling Yiqi Tablets (a Chinese herbal formula containing Astragalus, Codonopsis, and other herbs)
What this could lead to
If successful, this could offer a new option to help people with HIV rebuild their immune system when standard therapy alone is not enough.
What could go wrong
This is a relatively small, early-stage trial. The herbal tablets may not improve immune function, and there could be side effects or interactions with HIV medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED IMMUNODEFICIENCY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing University of Traditional Chinese Medicine

    Beijing, Beijing Municipality, 100029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.